Nutrafol’s latest product ushers the brand into new (hair care) territory. And it’s a terrific option for guys with short ...

The FDA said it does not intend to take action against 503B drug compounders for 90 days, or until May 22, “to avoid unnecessary disruption to patient treatment.” Hims & Hers Chief ... sources to ...

A still from the 2025 Super Bowl commercial “Sick of the System,” from telehealth company Hims & Hers. © 2025 Fortune Media IP Limited. All Rights Reserved. Use ...

The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

GLP-1 drugs like Wegovy and Ozempic, which are made by Novo Nordisk (NVO), have seen a shortage since 2022 amid rising demand. While that shortage was in effect, it allowed compounders - drug makers ...

HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized ...

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...

Amplify Online Retail ETF reflects digital trends but faces stagnant growth. Learn why IBUY's exposure to economic challenges ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...